TherapeuticsMD reported full year 2025 financial results with net loss from continuing operations of $0.7 million and license revenue of $3.0 million, alongside ongoing evaluation of strategic alternatives.
Key takeaways
Net loss from continuing operations $(0.7) million or $(0.06) per share for 2025, improved $1.7 million from $(2.3) million or $(0.20) per share in 2024.
License revenue $3.0 million in 2025, up 71.6% or $1.3 million from $1.8 million in 2024, primarily from Mayne License Agreement.
Total operating expenses $7.4 million in 2025, down 5.9% or $0.5 million from $7.9 million in 2024.
Cash and cash equivalents $7.5 million as of December 31, 2025.
Company evaluating strategic alternatives including acquisition, merger, sale of assets or other transactions, no assurance of outcome.